Morning Anderson 101, PAA have only just completed a Rights Issue for Shareholders , they raised sufficient finance for the completion of Phase II in K9 which positive results would enable the Elanco Option. They have stated that they actually have enough to also begin prelim for Human Trials.
PAA have already been down this exact road,, the Treatment benefits were spectacular but overshadowed by poor palatability.. it's a Re-do but with a Palatable and Higher efficacy formulation..
They also have a $1.2m finance facility that they have been extremely prudent with ,,in fact have been paying down swathes from the Epichem revenue.. so if they fall short for the negotiating period have a cushion.. plus if they asked me for money in the next 3 months I'd gladly dig deep on this one...
Best of luck with your investments ,, the latest update is comprehensive,,, plus Management are about to start to prime the market on awareness,, ergo the Broker conferences ..
- Forums
- ASX - By Stock
- how far will this go?
Morning Anderson 101, PAA have only just completed a Rights...
-
- There are more pages in this discussion • 41 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add NUZ (ASX) to my watchlist
(20min delay)
|
|||||
Last
19.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $93.42M |
Open | High | Low | Value | Volume |
19.0¢ | 19.3¢ | 19.0¢ | $25.41K | 133.7K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 5372 | 19.0¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
19.5¢ | 262575 | 3 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 5372 | 0.190 |
8 | 586793 | 0.185 |
5 | 322800 | 0.180 |
6 | 151497 | 0.175 |
4 | 84250 | 0.170 |
Price($) | Vol. | No. |
---|---|---|
0.195 | 262575 | 3 |
0.200 | 37500 | 2 |
0.210 | 82780 | 3 |
0.215 | 180458 | 2 |
0.220 | 40000 | 1 |
Last trade - 16.10pm 08/11/2024 (20 minute delay) ? |
Featured News
NUZ (ASX) Chart |
The Watchlist
EQN
EQUINOX RESOURCES LIMITED.
Zac Komur, MD & CEO
Zac Komur
MD & CEO
SPONSORED BY The Market Online